Company intelligence / Profile preview

CPEX Pharmaceuticals, Inc.

Exeter, New Hampshire, United Statesprnewswire.com ↗
Ownership
Private
Development stage
Commercial
01

Overview

CPEX had a discontinued insulin inhalation product for Type 1 Diabetes. The company was acquired in 2011.

Therapeutic areas
Endocrinology
Modalities
Drug delivery technology
Industry
Biotech
02

Drug pipeline

2 assets

testosterone

Commercial
Indications
Hypogonadism

1 more asset in the full pipeline.

Request access →
03

Partnerships

Auxilium Pharmaceuticals, Inc.Biocon Biopharmaceuticals Pvt Ltd.

Beyond the preview

Go deeper on CPEX Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CPEX Pharmaceuticals, Inc..

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call